Dalbavancin Outpatient Pilot

Inclusion * \>=18 years of age * Provide informed consent * Agreement to attend required follow-up visits with reasonable transportation plan * Afebrile for at least 24 hours prior to enrollment * Expected survival ≥3 months * If female, non-pregnant and non-lactating; all females of child-bearing potential must have a negative pregnancy test prior to study entry and must agree to use a highly effective method of birth control during the study and for one month thereafter. * Anticipated hospital discharge within 8 days * Joint and bone infection: * Sterile site culture positive for susceptible organism * Participants with bacteremia and right-sided infective endocarditis (IE): * 2 or more blood cultures positive for S. aureus (MSSA or MRSA or Streptococci) * Blood cultures negative for 72 hours within 7 days on standard of care antibiotic therapy * Definite diagnosis of right sided infective endocarditis by Duke Criteria * Echocardiographic assessment (TTE or TEE) * For patients with opioid use disorder and history of injection opioid use, * Injection of opioid substances (IOS) in the last 6 months * Fulfill criteria for opioid use disorder Exclusion * Polymicrobial infection * Baseline QTc \>500 msec * Creatinine clearance \<30 mL per min * Immunocompromised from neutropenia, AIDS, malignancy, chemotherapy, or receiving immunosuppressant medication including systemic corticosteroids (intranasal or inhaled corticosteroids acceptable) * Patients with documented allergies to lipoglycopeptides, vancomycin, or teicoplanin * Concurrent diseases that, in the Investigator's medical judgment, would interfere with the conduct of the study, confound the interpretation of the study results, or endanger the patient's well-being * For participants with right-sided IE: * No mitral or aortic valve involvement on echocardiogram * Large, mobile vegetations (\>10mm) * Perivalvular abscess * Presence of an intracardiac device (defibrillator or pacer) or prosthetic valve